A non-coding m(6)A reader promotes leukaemia

Pathways linked to the modification of RNA with N-6-methyladenosine (m(6)A) are known to be involved in initiating and maintaining cancer. But many of the key components of these pathways remain undiscovered. The RBFOX2 protein has now been identified as an m(6)A reader involved in locus-specific chromatin regulation, with therapeutic implications for myeloid leukaemia.

Automated summary

Research shows that pathways associated with RNA modification with N-6-methyladenosine (m(6)A) play a role in cancer initiation and maintenance, but many important components of these pathways remain unknown. The RBFOX2 protein has been identified as an m(6)A reader involved in locus-specific chromatin regulation, with potential therapeutic implications for myeloid leukaemia.